About the Authors

Dag Tidemalm

dag.tidemalm@ki.se

Affiliation Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden

Axel Haglund

Affiliation Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden

Alina Karanti

Affiliation Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden

Mikael Landén

Affiliations Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Bo Runeson

Affiliation Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm, Sweden

Competing Interests

ML has, over the past 36 months, received compensation for lectures from AstraZeneca, Bayer, Biophausia, Bristol Myers-Squibb, Lundbeck Pharmaceuticals, Eli Lilly Sweden, Wyeth, Servier Sweden, and served at advisory board for AstraZeneca and Lundbeck pharmaceuticals. AK has, over the past 36 months, received compensation for lectures from Eli Lilly Sweden. BR has, over the past 36 months, received compensation for lectures from AstraZeneca, Lundbeck Pharmaceuticals, and Eli Lilly Sweden. The other authors have nothing to disclose. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: BR ML DT. Performed the experiments: DT. Analyzed the data: DT AH AK ML BR. Contributed reagents/materials/analysis tools: ML DT. Wrote the paper: DT AH AK ML BR.